File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The use of atorvastatin for chronic subdural haematoma: a retrospective cohort comparison study

TitleThe use of atorvastatin for chronic subdural haematoma: a retrospective cohort comparison study
Authors
KeywordsChronic Subdural Haematoma
elderly trauma
head injury
head trauma
manuscript
statin
Issue Date2017
Citation
British Journal of Neurosurgery, 2017, v. 31, n. 1, p. 72-77 How to Cite?
AbstractChronic subdural haematoma (CSDH) is a common neurosurgical condition. Burr-hole for drainage is an effective treatment. However, recurrence can be up to 8–33% and is associated with morbidities and mortalities. The underlying pathogenesis was postulated to be localised inflammation and pathological aberrant vessels formation. Atorvastatin, an HMG-CoA reductase inhibitor, is a type of lipid-lowering medication. In animal studies and a preliminary clinical trial, Atorvastatin was shown to be effective in the treatment of CSDH. It was found to inhibit inflammation and promote vascular maturation at the neomembrane of CSDH. Our study aimed to investigate the efficacy of Atorvastatin in CSDH. During the study period from January to December 2014, Atorvastatin was used in 12 CSDH patients with Glasgow Coma Scale (GCS) 13–15 or Markwalder’s Grading Scale (MGS) Grade 0–2. They were retrospectively compared with GCS- and MGS-matched controls who had not used statin. Improvement with haematoma resolution at 3 months was 75% (9/12) for the Atorvastatin group, versus 42% (5/12) for the Control group (p = 0.0977). The risk of deterioration requiring burr-hole drainage was 16.7% (2/12) in the Atorvastatin group, versus 58.3% (7/12) in the Control group (p = 0.0447). The Odds Ratio (OR) of deterioration requiring burr-hole drainage with Atorvastatin was 0.143 (95%CI: 0.021–0.958), which favours the use of Atorvastatin in CSDH (p = 0.0451). The Number needed to treat (NNT) was 2.4 (p = 0.0447; 95%CI: 1.31–14.93). In conclusion, this retrospective cohort comparison study has shown that CSDH with Atorvastatin had a lower rate of deterioration and burr-hole drainage.
Persistent Identifierhttp://hdl.handle.net/10722/325334
ISSN
2023 Impact Factor: 1.0
2023 SCImago Journal Rankings: 0.402
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, David Yuen Chung-
dc.contributor.authorChan, Danny Tat Ming-
dc.contributor.authorSun, Tin Fung David-
dc.contributor.authorNg, Stephanie Chi Ping-
dc.contributor.authorWong, George Kwok Chu-
dc.contributor.authorPoon, Wai Sang-
dc.date.accessioned2023-02-27T07:31:38Z-
dc.date.available2023-02-27T07:31:38Z-
dc.date.issued2017-
dc.identifier.citationBritish Journal of Neurosurgery, 2017, v. 31, n. 1, p. 72-77-
dc.identifier.issn0268-8697-
dc.identifier.urihttp://hdl.handle.net/10722/325334-
dc.description.abstractChronic subdural haematoma (CSDH) is a common neurosurgical condition. Burr-hole for drainage is an effective treatment. However, recurrence can be up to 8–33% and is associated with morbidities and mortalities. The underlying pathogenesis was postulated to be localised inflammation and pathological aberrant vessels formation. Atorvastatin, an HMG-CoA reductase inhibitor, is a type of lipid-lowering medication. In animal studies and a preliminary clinical trial, Atorvastatin was shown to be effective in the treatment of CSDH. It was found to inhibit inflammation and promote vascular maturation at the neomembrane of CSDH. Our study aimed to investigate the efficacy of Atorvastatin in CSDH. During the study period from January to December 2014, Atorvastatin was used in 12 CSDH patients with Glasgow Coma Scale (GCS) 13–15 or Markwalder’s Grading Scale (MGS) Grade 0–2. They were retrospectively compared with GCS- and MGS-matched controls who had not used statin. Improvement with haematoma resolution at 3 months was 75% (9/12) for the Atorvastatin group, versus 42% (5/12) for the Control group (p = 0.0977). The risk of deterioration requiring burr-hole drainage was 16.7% (2/12) in the Atorvastatin group, versus 58.3% (7/12) in the Control group (p = 0.0447). The Odds Ratio (OR) of deterioration requiring burr-hole drainage with Atorvastatin was 0.143 (95%CI: 0.021–0.958), which favours the use of Atorvastatin in CSDH (p = 0.0451). The Number needed to treat (NNT) was 2.4 (p = 0.0447; 95%CI: 1.31–14.93). In conclusion, this retrospective cohort comparison study has shown that CSDH with Atorvastatin had a lower rate of deterioration and burr-hole drainage.-
dc.languageeng-
dc.relation.ispartofBritish Journal of Neurosurgery-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectChronic Subdural Haematoma-
dc.subjectelderly trauma-
dc.subjecthead injury-
dc.subjecthead trauma-
dc.subjectmanuscript-
dc.subjectstatin-
dc.titleThe use of atorvastatin for chronic subdural haematoma: a retrospective cohort comparison study-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1080/02688697.2016.1208806-
dc.identifier.pmid27881024-
dc.identifier.scopuseid_2-s2.0-84996937966-
dc.identifier.volume31-
dc.identifier.issue1-
dc.identifier.spage72-
dc.identifier.epage77-
dc.identifier.eissn1360-046X-
dc.identifier.isiWOS:000394397400016-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats